Schedule 13D ownership disclosure
PMV PHARMACEUTICALS INC
COMMON STOCK · CUSIP: 69353Y103
Event date: 2025-10-23
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- ORBIMED ADVISORS LLCReported CIK 0001055951
Shares: 4,975,291.00 · Class: 9.4%
- ORBIMED CAPITAL GP V LLCReported CIK 0001615374
Shares: 4,975,291.00 · Class: 9.4%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000947871-25-000926
- Form type
- SCHEDULE 13D/A
- Filer
- ORBIMED ADVISORS LLC
- CIK
- CIK 1055951
- Filed
- Oct 27, 2025
- Reporting period
- Oct 23, 2025
- Description
- Schedule 13D beneficial ownership